Zealand Pharma A/S, of Copenhagen, started a multinational phase III trial with dasiglucagon in four countries (Austria, Germany, Canada and the U.S.).
Steadymed Ltd., of San Ramon, Calif., has submitted an FDA new drug application for its lead candidate, Trevyent (treprostinil), for the treatment of pulmonary arterial hypertension.
If Qu Biologics Inc. CEO Hal Gunn was dismayed at presenting the company's poster in the back of the colossal exhibit hall at Chicago's McCormick Place during Digestive Disease Week (DDW) in May, he didn't complain.
LONDON – The EU has set out a new plan for tackling antimicrobial resistance (AMR) and delivered the first item on the to-do list in the form of guidelines for adoption by all member states on the prudent use of antimicrobial drugs in humans.
Changes in the 3-D organization of chromosomes in neurons affected the expression of genes that are important for the formation of neuronal connections and that have been implicated in schizophrenia risk, researchers at the Mount Sinai School of Medicine reported in the July 3, 2017, issue of Nature Genetics.
LONDON – The U.K.'s chief medical officer (CMO) has issued a call to "democratize genomics" and make DNA sequencing an "expected part of care" for all patients with cancer or a rare disease.
"Promises are not the yardstick against which utility is to be measured," the Supreme Court of Canada said in a unanimous ruling Friday that struck down the so-called Promise Doctrine, a judicial test lower courts have used to invalidate 26 patents covering 22 drugs over the past 12 years.
A rising interest in the neurodegenerative (ND) disease space has sparked a flurry of high-money deals, with the last three years indicating a doubling in the number of collaborations and licensing agreements, plus an 87 percent incline in deal value, when compared to the previous three years.
RSS